home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

26.46 -0.32 (-1.19%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

AMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024 ↗

May 08, 2024

AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024

May 08, 2024

Via ACCESSWIRE

Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca ↗

May 01, 2024

The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, and COPD medications. This initiative combats tactics hindering generic...

Via Benzinga

Topics Intellectual Property

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2024

April 30, 2024

Via ACCESSWIRE

Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies ↗

April 10, 2024

Amphastar Pharmaceuticals discusses the future of Baqsimi at the Needham Healthcare Conference, highlighting its potential amid a growing market for glucagon products. With promising sales projections...

Via Benzinga

NASDAQ:AMPH, an undervalued stock with good fundamentals. ↗

March 12, 2024

AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH): good value for what you're paying.

Via Chartmill

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2023

February 28, 2024

Via ACCESSWIRE

Delving into NASDAQ:AMPH's Growth Prospects. ↗

February 28, 2024

Should you consider AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) for growth investing?

Via Chartmill

Amphastar Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference

April 01, 2024

Via ACCESSWIRE

Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference

March 06, 2024

Via ACCESSWIRE

Earnings Outlook For Amphastar Pharma ↗

February 27, 2024

Via Benzinga

Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2024

February 20, 2024

Via ACCESSWIRE

Is NASDAQ:AMPH a Fit for Growth Investing Strategies? ↗

February 14, 2024

Is AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) suited for growth investing?

Via Chartmill

CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+ ↗

February 13, 2024

CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

Is NASDAQ:AMPH a Fit for Growth Investing Strategies? ↗

February 07, 2024

Why AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) qualifies as a high growth stock.

Via Chartmill

Unlocking the Growth Potential of NASDAQ:AMPH. ↗

January 23, 2024

Exploring AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH)'s growth characteristics.

Via Chartmill

NASDAQ:AMPH is not too expensive for the growth it is showing. ↗

January 17, 2024

Looking for growth without the hefty price tag? Consider NASDAQ:AMPH.

Via Chartmill

3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential ↗

February 05, 2024

As the new business cycle gets started, here are some biotech stocks with potential that investors should pay attention to.

Via InvestorPlace

Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating ↗

January 23, 2024

Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

Despite its impressive fundamentals, NASDAQ:AMPH remains undervalued. ↗

January 23, 2024

For those who appreciate value investing, AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) is a compelling option with its solid fundamentals.

Via Chartmill

What Vitamins Did For Healthy Living, Stemtech Corporation (OTCQB: STEK) Says It Is Doing For Anti-Aging With Stem Cell Nutrition ↗

January 19, 2024

Vitamins may not be a miracle cure, but combined with exercise and a healthy diet, they have the potential to greatly improve health and wellness. It’s no wonder vitamin supplements are a multi-billion...

Via Benzinga

Jim Cramer Says Hold Onto This Biotech Stock: 'I Don't Understand Why It's So Inexpensive' ↗

January 17, 2024

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would back Moderna, Inc. (NASDAQ: MRNA) here.

Via Benzinga

Why NASDAQ:AMPH is Poised for High Growth. ↗

January 16, 2024

Exploring AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH)'s growth characteristics.

Via Chartmill

Why AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) qualifies as a high growth stock. ↗

January 02, 2024

Is AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) suited for growth investing?

Via Chartmill

Cassava Sciences Stock Continues Showing Rising Relative Strength ↗

January 16, 2024

Cassava Sciences sees its Relative Strength Rating move into the elite 90-plus level.

Via Investor's Business Daily

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗

January 05, 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

Via Investor's Business Daily

Amphastar Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 02, 2024

Via ACCESSWIRE

Cytokinetics Stock Jumps To Higher RS Level; Shoots Up On Heart Drug Study ↗

December 28, 2023

On Thursday, Cytokinetics stock cleared a key performance benchmark, with its Relative Strength Rating jumping to 99 from 89 the day before.

Via Investor's Business Daily

Should you consider NASDAQ:AMPH for growth investing? ↗

December 26, 2023

Is AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) suited for growth investing?

Via Chartmill

Recursion Pharm Showing Market Leadership As Biotech Stocks Shoot Higher ↗

December 26, 2023

On Tuesday, Recursion Pharm stock reached a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88 the day before.

Via Investor's Business Daily

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com